Weaned From Bristol-Myers Squibb, Mead Johnson Expands With Nutritional Baby Formula

SUGAR LAND--December 7, 2009--Researched by Industrial Info Resources (Sugar Land, Texas)--Bristol-Myers Squibb (NYSE:BMY) (New York, New York) is divesting its 83% majority stake in its last non-biopharmaceutical holding, Mead Johnson Nutritional (NYSE:MJN) (Evansville, Indiana). This divesture comes only 10 months after Mead Johnson's initial public offering. In this time, Mead Johnson's stock has almost doubled from $24 per share to about $43 per share, and the company has embarked on a major and non-traditional expansion at its Evansville site.